Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.68 |
| ▸ | RAB9A | P51151 | 10/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620629 | 0.86 | NPC1 (0.61) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL29899082 | 0.86 | NPC1 (0.61) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL2862565 | 0.84 | NPC1 (0.68) | NPC1RAB9APKMNPSR1KMT2A | |
| SCHEMBL2682648 | 0.81 | RAB9A (1.00) | NPC1RAB9APKMNPSR1KMT2A | |
| SCHEMBL29078756 | 0.79 | NPC1 (0.62) | NPC1RAB9APKMNPSR1KMT2A | |
| SCHEMBL3662241 | 0.78 | EPHX1 (0.67) | NPC1RAB9ANPSR1KCNH2EPHX1 | |
| SCHEMBL2832098 | 0.78 | NPC1 (0.72) | NPC1RAB9APKMNPSR1KCNH2 | |
| SCHEMBL15012132 | 0.77 | NPC1 (0.58) | NPC1RAB9APKMNPSR1KCNH2 | |
| SCHEMBL27039938 | 0.77 | NPC1 (0.58) | NPC1RAB9APKMNPSR1KMT2A | |
| SCHEMBL18342290 | 0.76 | ALDH1A1 (0.72) | NPC1RAB9AKMT2AEPHX1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | NPC1 2234/4885RAB9A 1031/4885PKM 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.